Results 221 to 230 of about 85,599,608 (253)

Neointimal Hyperplasia and Restenosis: Epidemiology, Pathophysiology, Animal Models, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 11, November 2026.
The overall graphical diagram to summarize the pathological characteristics, pathogenesis, clinical manifestation, preclinical animal models, diagnostic methods, and intervention strategies for neointimal hyperplasia. Neointimal hyperplasia results from excessive proliferation and intimal migration of vascular smooth muscle cells (VSMCs) in the ...
Kaixu Wang, Daiyu Zhang, Yu Hu, Yixin Zhao, Xinling Wang, Long Jiang, Meixiu Jiang   +6 more
wiley   +1 more source

Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study. [PDF]

Diabetol Int
Koto R, Yoshida S, Nakajima A, Miwa T, Nishimura R.   +4 more
europepmc   +1 more source

Target Trial Emulation or Target Trial Approximation?

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Target trial emulation has contributed to improvements in the design and interpretation of observational studies aimed at causal inference. By encouraging researchers to think explicitly about the design of a hypothetical randomized trial, it has helped identify and address avoidable design flaws.
Priya Vart
wiley   +1 more source

Target‐Engagement Prediction From Molecular Structure, In Vitro and Animal Data: A Tutorial for Early Assessment of Clinical Drug Exposure and Therapeutic/Adverse Potential Using the ANDROMEDA and PLATO Software on the InSilicoTrials Platform

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT The target‐engagement predictor, implemented within the InSilicoTrials cloud‐based, AI‐powered platform for model‐informed drug discovery and development, enables early exploration of time‐dependent pharmacological responses. Predictions can be generated using inputs ranging from molecular structure to in vitro, animal, and clinical data ...
Niccolò Totis, Fianne Sips, Simona Catozzi, Marc‐Antonio Bisotti, Pauline Bambury, Sofia Stathopoulos, Vincenzo Carbone, Luca Emili, Mario Torchia, Valentina Belgiovine, Fulvio Ciriaco, Orazio Nicolotti, Urban Fagerholm, Candice N. Baker, J. Matthew Mahoney, Daniel Röshammar, on behalf of the CARDIOVERSE Project   +16 more
wiley   +1 more source

PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes. [PDF]

Diabetes Metab Syndr Obes
Penaforte-Saboia JG, Couri CEB, Albuquerque NV, Linard LLP, Araújo DAC, de Oliveira SKP, Gomes TFP, Pinheiro MM, Castelo MHCG, Fernandes VO, Montenegro Júnior RM.   +10 more
europepmc   +1 more source

Dysglycaemia and Autonomic Dysfunction: The Diabetes Prevention Program Outcomes Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10743-10752, November 2026.
ABSTRACT Aim Limited data on the link between various measures of glycemia and metabolism and autonomic dysfunction exist. We assessed the association of fasting plasma glucose [FPG], glycated haemoglobin [HbA1C], fasting insulin, and HOMA‐IR and cardiac autonomic function measures separately for men and women in the Diabetes Prevention Program ...
Justin B. Echouffo‐Tcheugui, Xun Liu, Elsayed Z. Soliman, Xavier Pi‐Sunyer, Sherita H. Golden, Sam Dagogo‐Jack, Neil H. White, Matthew Budoff, Uzoma Ibebuogu, Christine Darwin, William C. Knowler, Marinella Temprosa, on behalf of the DPP Research Group   +12 more
wiley   +1 more source

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. [PDF]

Diabetologia
Elbarbary NS, Ismail EA, El-Hamamsy MH, Ibrahim MZ, Elkholy AA.   +4 more
europepmc   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10018-10027, November 2026.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du, Giselle Sarganas, Beate Gaertner, Maike Buchmann, Judith Fuchs, Hannelore Neuhauser, Christin Heidemann   +6 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Association of GLP‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10037-10044, November 2026.
ABSTRACT Aims Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with
Masaya Koshizaka, Ryoichi Ishibashi, Tomoki Ishikawa, Kazuo Goda, Jumpei Sato, Masaru Kitsuregawa, Koutaro Yokote, Naohiro Mitsutake   +7 more
wiley   +1 more source